Pittsburgh Allegheny

Pittsburgh man accused of dealing heroin-fentanyl mix that caused overdose death

Natasha Lindstrom
By Natasha Lindstrom
1 Min Read Aug. 19, 2019 | 6 years Ago
Go Ad-Free today

A federal grand jury indicted a Pittsburgh man on charges of delivering the heroin and fentanyl mix that resulted in a drug user dying of an overdose last year, prosecutors said Monday.

Davonte Dugger, 20, faces narcotics charges stemming from a Drug Enforcement Administration investigation into the overdose death and related drug-dealing during the fall of 2018, U.S. Attorney Scott W. Brady said.

The grand jury’s three-count indictment accuses Dugger of selling heroin and fentanyl on Aug. 7, 2018, that caused serious bodily injury and the death of a person.

A judge unsealed the July 23 indictment last week.

Officials did not name the person who died in a news release. Court records do not yet provide further details.

Dugger is the only defendant in the case regarding the fatal overdose, according to Brady.

Dugger also is accused of possessing with the intent to distribute quantities of heroin, fentanyl and acetyl fentanyl on at least two other occasions in October.

The DEA conducted the investigation with help from Moon Township police.

Assistant U.S. Attorney Mark V. Gurzo is prosecuting the case.

If convicted, Dugger faces up a possible sentence of not less than 20 years and up to life in prison and a fine up to $7 million.

He is set to be arraigned Friday morning before Judge Patricia L. Dodge.

Share

Categories:

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options